Related Experiment Video
Updated: Apr 23, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Effect of High Dose Rosuvastatin Loading before Percutaneous Coronary Intervention on Contrast-Induced Nephropathy
Kyeong Ho Yun1, Jae Hong Lim1, Kyo Bum Hwang1
1Department of Cardiovascular Medicine, Regional Cardiocerebrovascular Center, Wonkwang University Hospital, Iksan, Korea.
Insights
High-dose rosuvastatin loading before percutaneous coronary intervention (PCI) significantly reduced contrast-induced nephropathy (CIN) in acute coronary syndrome (ACS) patients. This statin pretreatment offers a protective effect against kidney injury post-PCI.
Area of Science:
- Cardiology
- Nephrology
- Pharmacology
Background:
- Contrast-induced nephropathy (CIN) increases morbidity and mortality in patients undergoing percutaneous coronary intervention (PCI).
- Identifying effective preventative strategies for CIN is crucial in managing patients with acute coronary syndrome (ACS).
Purpose of the Study:
- To evaluate the efficacy of high-dose rosuvastatin loading prior to PCI in preventing CIN among ACS patients.
- To assess the impact of rosuvastatin on renal function markers post-PCI.
Main Methods:
- An observational study involving 824 ACS patients undergoing PCI.
- Patients received either 40 mg rosuvastatin loading (statin group, n=408) or no pretreatment (control group, n=416).
- Serum creatinine and estimated glomerular filtration rate (eGFR) were monitored pre-PCI and up to 48 hours post-PCI.
Main Results:
- The incidence of CIN was significantly lower in the rosuvastatin group (13.5%) compared to the control group (18.8%), p=0.040.
- Rosuvastatin loading was independently associated with a decreased risk for CIN (OR, 0.64; 95% CI, 0.43-0.95; p=0.026).
- Protective effects were more pronounced in subgroups with diabetes, high contrast volume, multivessel disease, elevated CRP, and myocardial infarction.
Conclusions:
- High-dose rosuvastatin loading before PCI is an effective strategy for reducing CIN incidence in ACS patients.
- Pre-PCI rosuvastatin administration demonstrates a significant protective effect on renal function following the procedure.
Background And Objectives:
Contrast-induced nephropathy (CIN) is associated with increased morbidity and mortality. This observational, non-randomized study evaluated the effect of rosuvastatin loading before percutaneous coronary intervention (PCI) on the incidence of CIN in patients with acute coronary syndrome (ACS).
Subjects And Methods:
A total of 824 patients who underwent PCI for ACS were studied (408 patients in the statin group=40 mg rosuvastatin loading before PCI; 416 patients of control group=no statin pretreatment). Serum creatinine concentrations were measured before and 24 and 48 hours after PCI. The primary endpoint was development of CIN defined as an increase in serum creatinine concentration of ≥0.5 mg/dL or ≥25% above baseline within 72 hours after PCI.
Results:
The incidence of CIN was significantly lower in the statin group than that in the control group (18.8% vs. 13.5%, p=0.040). The maximum percent changes in serum creatinine and estimated glomerular filtration rate in the statin group within 48 hours were significantly lower than those in the control group (5.84±22.59% vs. 2.43±24.49%, p=0.038; -11.44±14.00 vs. -9.51±13.89, p=0.048, respectively). The effect of rosuvastatin on preventing CIN was greater in the subgroups of patients with diabetes, high-dose contrast medium, multivessel stents, high baseline C-reactive protein, and myocardial infarction. A multivariate analysis revealed that rosuvastatin loading was independently associated with a decreased risk for CIN (odds ratio, 0.64; 95% confidence interval, 0.43-0.95, p=0.026).
Conclusion:
High-dose rosuvastatin loading before PCI was associated with a significantly lower incidence of CIN in patients with ACS.
More Related Videos
Related Concept Videos
Cardiac Catheterization I: Pre-Procedure Overview
Imaging Studies for Cardiovascular System V: CT
Cardiac Catheterization IV: Nursing Management
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Imaging Studies VII: Vascular Imaging
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

